Drug Type Small molecule drug |
Synonyms + [2] |
Target |
Mechanism SLC7A5 inhibitors(L-type amino acid transporter 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC23H19Cl2N3O4 |
InChIKeyXNRZJPQTMQZBCE-SFHVURJKSA-N |
CAS Registry1037592-40-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Biliary Tract Neoplasms | Phase 3 | JP | - | |
Colorectal Cancer | Phase 2 | JP | - | |
Colorectal Cancer | Phase 2 | US | - | |
Renal Cell Carcinoma | Phase 1 | JP | - |
Phase 2 | 104 | (nzlycyrpgr): HR = 0.439 (95% CI, 0.2254 - 0.8535), P-Value = 0.0131 View more | Positive | 26 May 2023 | |||
placebo | |||||||
Phase 2 | 106 | (tjxtkiudwq) = significant improvement lkrkwctazt (msujlckclf ) Met | Positive | 24 Jan 2023 | |||
placebo | |||||||
Phase 1 | - | (femtrxyxmq) = Common treatment-related adverse events were increased ALT/AST, malaise, nausea, hypertension, and grade 1 or grade 2 fevers. qipeqsvvde (iskchqeehm ) View more | Positive | 01 Jun 2018 | |||
Phase 1 | 17 | (fdjumdxxgl) = Common treatment-related adverse events were increased ALT/AST, malaise, nausea, hypertension and fever of Grade 1 or 2. haawnkkwvy (wkhalxyqyr ) View more | Positive | 26 Feb 2018 |